Britannia Pharmaceuticals Limited Expands Nasal Powder Program With New Production Capability
10/19/2005 5:11:31 PM
Britannia Pharmaceuticals announced today that it has purchased a state-of-the art Omnidose system from Harro Hofliger GmbH to accelerate the development of its innovative nasal powder treatments. The Omnidose machine, which will be operated out of Cardinal Health Germany GmbH, will provide rapid, high-precision dosing of Britannia's apomorphine and dihydroergotamine (DHE) nasal powders for use in the company's late-stage development programs, through to commercial production. Apomorphine is a potent dopamine agonist used in the treatment of late-stage Parkinson's disease and erectile dysfunction. DHE is used to treat migraine headaches.
comments powered by